NextCODE Buy Boosts WuXi’s Genomics Expertise
This article was originally published in PharmAsia News
WuXi PharmaTech has acquired the genomic analysis company NextCODE Health for $65 million in cash. The Shanghai-based R&D technology firm plans to merge the NextCODE Health business into its own genome center, creating a new company to be known as WuXi NextCODE Genomics.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.